Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in kenyan children aged 1-4 years: A randomized controlled trial

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Hammitt, Laura L ^a,b   Ojal, John ^a   Bashraheil, Mahfudh ^a   Morpeth, Susan C ^a,c   Karani, Angela ^a   Habib, Ahsan ^d   Borys, Dorota ^d   Goldblatt, David ^e   Scott, J Anthony G ^a,c,f  

^a KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d GSK   (Belgium)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE VACCINE; HAEMOPHILUS INFLUENZAE VACCINE; HEPATITIS A VACCINE; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL LOAD; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; KENYA; MALE; NASOPHARYNX; NOSE SMEAR; OPSONIZATION; OPSONOPHAGOCYTIC KILLING ASSAY; PHASE 3 CLINICAL TRIAL; PNEUMOCOCCAL INFECTION; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; THROAT CULTURE; VACCINATION;

ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; CARRIER PROTEINS; CARRIER STATE; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DOUBLE-BLIND METHOD; FEMALE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; HEPATITIS A VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN D; INFANT; INFANT, NEWBORN; KENYA; LIPOPROTEINS; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 84908105384     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085459     Document Type: Article

References (34)

1. Berkley JA, Lowe BS, Mwangi I, Williams T, Bauni E, et al. (2005) Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med 352: 39-47. (Pubitemid 40075679)
2. Brent AJ, Ahmed I, Ndiritu M, Lewa P, Ngetsa C, et al. (2006) Incidence of clinically significant bacteraemia in children who present to hospital in Kenya: community-based observational study. Lancet 367: 482-8. (Pubitemid 43208904)
3. Centers for Disease Control and Prevention (2008) Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction-eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 57: 144-8.
4. Lucero MG, Dulalia VE, Nillos LT, Williams G, Parreno RA, et al. (2009) Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev CD004977.
5. Miller E, Andrews NJ, Waight PA, Slack MP, George RC (2011) Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 11: 760-8.
6. Poehling KA, Talbot TR, Griffin MR, Craig AS, Whitney CG, et al. (2006) Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 295: 1668-74.
7. Bermal N, Szenborn L, Chrobot A, Alberto E, Lommel P, et al. (2009) The 10- valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Pediatr Infect Dis J 28: S89-96.
8. Knuf M, Szenborn L, Moro M, Petit C, Bermal N, et al. (2009) Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr Infect Dis J 28: S97-S108.
9. Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, et al. (2009) Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 28: S66-76.
10. Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, et al. (2012) Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease in infants: a cluster randomized trial. Lancet 12: 61854-6.
11. Plikaytis BD, Goldblatt D, Frasch CE, Blondeau C, Bybel MJ, et al. (2000) An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study. J Clin Microbiol 38: 2043-50. (Pubitemid 30414313)
12. Henckaerts I, Durant N, De Grave D, Schuerman L, Poolman J (2007) Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine 25: 2518-27. (Pubitemid 46366133)
13. Romero-Steiner S, Libutti D, Pais LB, Dykes J, Anderson P, et al. (1997) Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 4: 415-22. (Pubitemid 27321773)
14. O'Brien KL, Nohynek H (2003) Report from a WHO Working Group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae. Pediatr Infect Dis J 22: e1-11.
15. Sandstedt SA, Zhang L, Patel M, McCrea KW, Qin Z, et al. (2008) Comparison of laboratory-based and phylogenetic methods to distinguish between Haemophilus influenzae and H. haemolyticus. Journal of Microbiological Methods 75: 369-71.
16. Maaroufi Y, De Bruyne JM, Heymans C, Crokaert F (2007) Real-time PCR for determining capsular serotypes of Haemophilus influenzae. Journal of Clinical Microbiology 45: 2305-8. (Pubitemid 47203816)
17. Dicko A, Santara G, Dicko Y, Barry A, Mahamar A, et al. (2012) Safety/reactogenicity and immunogencity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjgate vaccine in Malian children. In: 8th International Symposium on Pneumococci and Pneumococcal Diseases. Iguaçu Falls, Brazil.
18. Silfverdal SA, Prymula R, Traskine M, Habib A, Borys D, et al. (2012) Immunogenicity/reactogenicity of 2-dose catch-up vaccination with 10-valent pneumococal non-typeable Haemophilus influenzae protein-D conjugate vaccine during the fourth year of life. In: 8th International Symposium on Pneumococci and Pneumococcal Diseases. Iguaçu Falls, Brazil.
19. Lagos RE, Munoz AE, Levine MM, Lepetic A, Francois N, et al. (2011) Safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean children. Hum Vaccin 7: 511-22.
20. Vesikari T, Karvonen A, Korhonen T, Karppa T, Sadeharju K, et al. (2011) Immunogenicity of 10-valent pneumococcal nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine when administered as catch-up vaccination to children 7 months to 5 years of age. Pediatr Infect Dis J 30: e130-41.
21. Gray BM, Converse GM, 3rd, Dillon HC, Jr. (1980) Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis 142: 923-33. (Pubitemid 11153261)
22. Smillie WG, Jewett OF (1940) The relationship of immediate family contact to the transmission of type-specific pneumococci. Am J Hyg 32: 79-88.
23. Hammitt LL, Bruden DL, Butler JC, Baggett HC, Hurlburt DA, et al. (2006) Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis 193: 1487-94. (Pubitemid 43794576)
24. Dagan R, GIvon-Lavi N, Zamir O, Sikuler-Cohen M, Guy L, et al. (2002) Reduction in nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis 185: 927-36.
25. Binks MJ, Nelson J, O'Meara I, Kirkwood M, Wigger C, et al. (2012) Nasopharyngeal carriage of non-typeable Haemophilus influenzae in Australian indigenous children following vaccination with PhiD-CV10. In: 8th International Symposium on Pneumococci and Pneumococcal Diseases. Iguaçu Falls, Brazil.
26. Prymula R, Habib A, Fanic A, Borys D, Schuerman L (2012) Long-term effect of 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjgate vaccine on nasopharyngeal bacterial carriage in Czech children. In: 8th International Symposium on Pneumococci and Pneumococcal Diseases. Iguaçu Falls, Brazil.
27. van den Bergh MR, Spijkerman J, Swinnen K, Francois N, Pascal R, et al. (2012) Impact of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein-D conjugate vaccine on H. influenzae colonization: a randomized controlled trial. In: 8th International Symposium on Pneumococci and Pneumococcal Diseases. Iguaçu Falls, Brazil.
28. Hammitt LL, Akech D, Morpeth SC, Kihuha N, Karani A, et al. (2012) Reductions in nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus infleunzae 6 months after introduction of PCV10 in Kilifi, Kenya. In: 8th International Symposium on Pneumococci and Pneumococcal Diseases. Iguaçu Falls, Brazil.
29. World Health Organization (2009) Recommendations to ensure the quality, safety and efficacy of pneumococcal conjugate vaccines. In: WHO Technical Report Series.
30. Siber GR, Chang I, Baker S, Fernsten P, O'Brien KL, et al. (2007) Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 25: 3816-26. (Pubitemid 46589754)
31. Schuerman L, Wysocki J, Tejedor JC, Knuf M, Kim KH, et al. (2011) Prediction of pneumococcal conjugate vaccine effectiveness against invasive pneumococcal disesase using opsonophagocytic activity and antibody concentrations determined by enzyme-linked immunosorbent assay with 22F adsorption. Clin Vaccine Immunol 18: 2161-7.
32. Goldblatt D, Southern J, Ashton L, Richmond P, Burbidge P, et al. (2006) Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 25: 312-9.
33. O'Brien KL, Moisi J, Moulton LH, Madore D, Eick A, et al. (2007) Predictors of pneumococcal conjugate vaccine immunogenicity among infants and toddlers in an American Indian PnCRM7 efficacy trial. J Infect Dis 196: 104-14. (Pubitemid 46982744)
34. Abdullahi O, Karani A, Tigoi CC, Mugo D, Kungu S, et al. (2012) The prevalence and risk factors for pneumococcal colonization of the nasopharynx among children in Kilifi District, Kenya. PLoS ONE 7: e30787.